4-amino-7-(β-D-ribofuranosyl)-7H-pyrazolo[3,4-d][1,2,3]triazine | 35965-39-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-amino-7-(β-D-ribofuranosyl)-7H-pyrazolo[3,4-d][1,2,3]triazine
• 英文别名: 7-deaza-2,8-diazaadenosine；(2R,3R,4S,5R)-2-(4-aminopyrazolo[3,4-d]triazin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 35965-39-0
• 化学式: C₉H₁₂N₆O₄
• 分子量: 268.232
• InChiKey: CFIATHHTHPGSJS-MWKIOEHESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  152
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  4-amino-7-(β-D-ribofuranosyl)-7H-pyrazolo[3,4-d][1,2,3]triazine 在 吡啶 、 咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 63.67h， 生成
  参考文献：
  名称：

  [EN] MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS
  [FR] COMPOSÉS DI-NUCLÉOSIDIQUES CYCLIQUES MODIFIÉS SERVANT DE MODULATEURS STING

  摘要：

  本文提供了Formula (I)、Formula (II)和/或Formula (III)的化合物，或者上述任何一个的药用盐，包括本文描述的化合物（包括本文描述的化合物的药用盐）的药物组合物和合成方法。本文还提供了使用Formula (I)、Formula (II)和/或Formula (III)的化合物，或者上述任何一个的药用盐来治疗疾病和/或症状的方法。

  公开号：

  WO2020227421A1
• 作为产物：
  描述：

  7-(β-D-ribofuranosyl)imidazo<1,2-c>pyrazolo<4,3-e>pyrimidine 在 sodium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 溶剂黄146 、 sodium nitrite 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 4-amino-7-(β-D-ribofuranosyl)-7H-pyrazolo[3,4-d][1,2,3]triazine
  参考文献：
  名称：

  1,N6-Etheno-7-deaza-2,8-diazaadenosine: syntheses, properties and conversion to 7-deaza-2,8-diazaadenosine

  摘要：

  1,N6-Etheno-7-去氮-2,8-二氮腺苷（4）以64%的总产率从8-氮杂-7-去氮腺苷（6）合成。原料6是通过8-氮杂-7-去氮腺嘌呤（7）与1-O-乙酰基-2,3,5-三-O-苯甲酰基-β-D-呋喃核糖（8）直接糖基化获得的（NO2 CH3, BF3·Et2O; 产率77%）。化合物4被转化为7-去氮-2,8-二氮腺苷（5）。化合物4的荧光显示在531 nm处有最大发射峰（磷酸盐缓冲液；pH 7.0），与1,N6-乙烯基-2-氮杂腺苷（3a）（495 nm）相比，发生了向红端偏移。在固态和溶液中进行了构象分析。

  DOI：

  10.1039/b418849g

文献信息

• 1,N6-Etheno-7-deaza-2,8-diazaadenosine: syntheses, properties and conversion to 7-deaza-2,8-diazaadenosine
  作者：Wenqing Lin、Hong Li、Xin Ming、Frank Seela

  DOI：10.1039/b418849g

  日期：——

  1,N6-Etheno-7-deaza-2,8-diazaadenosine (4) was synthesized from 8-aza-7-deazaadenosine (6) in 64% overall yield. The starting material 6 was obtained by the direct glycosylation of 8-aza-7-deazaadenine (7) with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (8) (NO2 CH3, BF3·Et2O; 77% yield). Compound 4 was transformed into 7-deaza-2,8-diazaadenosine (5). The fluorescence of compound 4 shows an emission maximum at 531 nm (phosphate buffer; pH 7.0), which is bathochromically shifted compared to 1,N6-etheno-2-azaadenosine (3a) (495 nm). A conformational analysis was performed in the solid state and in solution.

  1,N6-Etheno-7-去氮-2,8-二氮腺苷（4）以64%的总产率从8-氮杂-7-去氮腺苷（6）合成。原料6是通过8-氮杂-7-去氮腺嘌呤（7）与1-O-乙酰基-2,3,5-三-O-苯甲酰基-β-D-呋喃核糖（8）直接糖基化获得的（NO2 CH3, BF3·Et2O; 产率77%）。化合物4被转化为7-去氮-2,8-二氮腺苷（5）。化合物4的荧光显示在531 nm处有最大发射峰（磷酸盐缓冲液；pH 7.0），与1,N6-乙烯基-2-氮杂腺苷（3a）（495 nm）相比，发生了向红端偏移。在固态和溶液中进行了构象分析。
• MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS
  申请人：ALIGOS THERAPEUTICS, INC.

  公开号：US20200369711A1

  公开（公告）日：2020-11-26

  Provided herein are compounds of Formula (I), Formula (II) and/or Formula (III), or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), Formula (II) and/or Formula (III), or a pharmaceutically acceptable salt of any of the foregoing.
• 7-SUBSTITUTED 8-AZA-7-DEAZAPURINES AND 2,8-DIAZA-7-DEAZA-PURINES: SYNTHESIS OF NUCLEOSIDES AND OLIGONUCLEOTIDES
  作者：Wenqing Lin、Kuiying Xu、Frank Seela

  DOI：10.1081/ncn-200059218

  日期：2005.4.1

  7-Substituted 8-aza-7-deazaadenosines la-e were synthesized by Sonogashira cross coupling from the corresponding 7-iodo nucleoside in 36- 79% yields. Starting from 7-bromo (or 7-iodo)-8-aza- 7-deazaadenine, 2a,b were obtained by acid-catalyzed glycosylation followed by deprotection in 53 and 35% yields, respectively. Compounds 2b was applied to cross coupling reaction to give 2c-d in 34-95% yield. Compounds 2a and 4b were further transformed to the phosphoramidites 5 and 6b in 9 and 49% overall yields, which were incorporated into oligonucleotides.
• [EN] MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS<br/>[FR] COMPOSÉS DI-NUCLÉOSIDIQUES CYCLIQUES MODIFIÉS SERVANT DE MODULATEURS STING
  申请人：ALIGOS THERAPEUTICS INC

  公开号：WO2020227421A1

  公开（公告）日：2020-11-12

  Provided herein are compounds of Formula (I), Formula (II) and/or Formula (III), or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), Formula (II) and/or Formula (III), or a pharmaceutically acceptable salt of any of the foregoing.

  本文提供了Formula (I)、Formula (II)和/或Formula (III)的化合物，或者上述任何一个的药用盐，包括本文描述的化合物（包括本文描述的化合物的药用盐）的药物组合物和合成方法。本文还提供了使用Formula (I)、Formula (II)和/或Formula (III)的化合物，或者上述任何一个的药用盐来治疗疾病和/或症状的方法。